REFERENCES
1 Singer DE, Hellkamp AS, Piccini JP, et al. Impact of global
geographic region on time in therapeutic range on warfarin anticoagulant
therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc2013;2 :e000067. doi:10.1161/JAHA.112.000067
2 Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral
anticoagulant over antiplatelet therapy in atrial fibrillation depends
on the quality of international normalized ratio control achieved by
centers and countries as measured by time in therapeutic range.Circulation 2008;118 :2029–37.
doi:10.1161/CIRCULATIONAHA.107.750000
3 Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety
of dabigatran compared with warfarin at different levels of
international normalised ratio control for stroke prevention in atrial
fibrillation: An analysis of the RE-LY trial. Lancet2010;376 :975–83. doi:10.1016/S0140-6736(10)61194-4
4 Oldgren J, Healey JS, Ezekowitz M, et al. Variations in cause
and management of atrial fibrillation in a prospective registry of 15
400 emergency department patients in 46 countries: The RE-LY atrial
fibrillation registry. Circulation 2014;129 :1568–76.
doi:10.1161/CIRCULATIONAHA.113.005451
5 Zühlke L, Engel ME, Karthikeyan G, et al. Characteristics,
complications, and gaps in evidence-based interventions in rheumatic
heart disease: The Global Rheumatic Heart Disease Registry (the REMEDY
study). Eur Heart J 2015;36 :1115–22.
doi:10.1093/eurheartj/ehu449
6 Makubi A, Lwakatare J, Nordrehaug J, et al. Anticoagulant
Control Results among Patients with Mechanical Heart Valves at Muhimbili
National hospital, Tanzania. Tanzania Med J2008;23 :12–6. doi:10.4314/tmj.v23i1.39222
7 Manji I, Pastakia SD, Do AN, et al. Performance outcomes of a
pharmacist-managed anticoagulation clinic in the rural,
resource-constrained setting of Eldoret, Kenya. J Thromb Haemost2011;9 :2215–20. doi:10.1111/j.1538-7836.2011.04503.x
8 Menanga A, Sibetcheu A, Chelo D, et al. Surveillance du
Traitement par Antivitamines K chez des Patients en Fibrillation
Auriculaire à Yaoundé. Heal Sci Dis2015;16 :1–6.https://www.hsd-fmsb.org/index.php/hsd/article/view/487
9 Daba FB, Tadesse F, Engidawork E. Drug-related problems and potential
contributing factors in the management of deep vein thrombosis.BMC Hematol 2016;16 :2. doi:10.1186/s12878-016-0043-y
10 Mariita K, Maina C, Nyamu D, et al. Patient factors impacting
on oral anticoagulation therapy among adult outpatients in a Kenyan
referral hospital. African J Pharmacol Ther2016;5 :193–200.http://journals.uonbi.ac.ke/ajpt/article/view/1534
11 Sadhabiriss D. Warfarin: Time in Therapeutic Range, a Single
Centre Study on Patients using Warfarin for Stroke Prevention in
Non-Valvular Atrial Fibrillation and Prosthetic Heart Valves .
2016.http://hdl.handle.net/10413/16021
12 Sonuga BO, Hellenberg DA, Cupido CS, et al. Profile and
anticoagulation outcomes of patients on warfarin therapy in an urban
hospital in Cape Town, South Africa. African J Prim Heal Care Fam
Med 2016;8 :a1032. doi:10.4102/phcfm.v8i1.1032
13 Ahmed NO, Osman B, Abdelhai YM, et al. Impact of clinical
pharmacist intervention in anticoagulation clinic in Sudan. Int J
Clin Pharm 2017;39 :769–73. doi:10.1007/s11096-017-0475-x
14 Fenta TG, Assefa T, Alemayehu B. Quality of anticoagulation
management with warfarin among outpatients in a tertiary hospital in
Addis Ababa, Ethiopia: a retrospective cross-sectional study. BMC
Health Serv Res 2017;17 :389. doi:10.1186/s12913-017-2330-0
15 Nyamu DG, Guantai AN, Osanjo GO, et al. Predictors of Adequate
Ambulatory Anticoagulation among Adult Patients in a Tertiary Teaching
and Referral Hospital in Kenya. African J Pharmacol Ther2017;6 :20–6.http://journals.uonbi.ac.ke/ajpt/article/view/1549
16 Coulibaly I, Diatema S, Hauhouot-Attoungbre M. Quality of oral
anticoagulation with Vitamin K antagonists assessed by the TTR in
ambulatory non-valvular atrial fibrillation patients (NVAF) at Abidjan
Institute of Cardiology. Trop Cardiol Published Online First:
2018.http://tropical-cardiology.com/Accueil/index.php/fr/2013-08-10-06-44-55/n-153-juil-aout-sep-2018/356-qualite-de-l-anticoagulation-orale-par-antivitamine-k-evaluee-par-le-calcul-du-ttr-chez-des-patients-traites-en-ambulatoire-pour-fibrillation-auriculaire-
17 Ebrahim I, Bryer A, Cohen K, et al. Poor anticoagulation
control in patients taking warfarin at a tertiary and district-level
prothrombin clinic in Cape Town, South Africa. South African Med
J 2018;108 :490–4. doi:10.7196/SAMJ.2018.v108i6.13062
18 Mwita JC, Francis JM, Oyekunle AA, et al. Quality of
Anticoagulation With Warfarin at a Tertiary Hospital in Botswana.Clin Appl Thromb 2018;24 :596–601.
doi:10.1177/1076029617747413
19 Jonkman LJ, Gwanyanya MP, Kakololo MN, et al. Assessment of
anticoagulation management in outpatients attending a warfarin clinic in
Windhoek, Namibia. Drugs Ther Perspect 2019;35 :341–6.
doi:10.1007/s40267-019-00630-y
20 Karuri S, Nyamu D, Opanga S, et al. Factors Associated with
Time in Therapeutic Range among Patients on Oral Anticoagulation Therapy
in a Tertiary Teaching and Referral Hospital in Kenya. East Cent
African J Pharm Sci2019;22 :85–95.http://uonjournals.uonbi.ac.ke/ojs/index.php/ecajps/article/view/293
21 Botsile E, Mwita JC. Incidence and risk factors for thromboembolism
and major bleeding in patients with mechanical heart valves: a tertiary
hospital-based study in Botswana. Cardiovasc J Afr 2020;:1–5.
doi:10.5830/CVJA-2020-006
22 Semakula JR, Mouton JP, Jorgensen A, et al. A cross-sectional
evaluation of five warfarin anticoagulation services in Uganda and South
Africa. PLoS One 2020;15 :e0227458.
doi:10.1371/journal.pone.0227458
23 Rwebembera J, Manyilirah W, Zhu ZW, et al. Prevalence and
characteristics of primary left-sided valve disease in a cohort of
15,000 patients undergoing echocardiography studies in a tertiary
hospital in Uganda. BMC Cardiovasc Disord 2018;18 :82.
doi:10.1186/s12872-018-0813-5
24 Yankah C, Fynn-Thompson F, Antunes M, et al. Cardiac surgery
capacity in sub-Saharan Africa: Quo Vadis? Thorac Cardiovasc Surg2014;62 :393–401. doi:10.1055/s-0034-1383723
25 Mandi DG, Bamouni J, Naïbé DT, et al. Epidemiology and
long-term prognosis of atrial fibrillation in rural African patients.Egypt Hear J 2019;71 :6. doi:10.1186/s43044-019-0005-3
26 Yameogo AR, Kologo JK, Mandi G, et al. Use of Vitamins K
antagonists in non-valvular atrial fibrillation thromboembolic risk
prevention in Burkina Faso. Pan Afr Med J 2016;24 :108.
doi:10.11604/pamj.2016.24.108.7100
27 Anakwue R, Ocheni S, Madu A. Utilization of oral anticoagulation in a
teaching hospital in Nigeria. Ann Med Health Sci Res2014;4 :286–90. doi:10.4103/2141-9248.141973
28 Alcheikh A, Chawe A, Kowa SF, et al. A comprehensive approach
to improving laboratory services in rural Zambia. Blood Adv2019;3 :11–5. doi:10.1182/bloodadvances.2019gs121633
29 Chalachew T, Yadeta D, Tefera E. Factors associated with sub-optimal
control of anticoagulation in patients with prosthetic heart valves
taking oral anticoagulants in a sub-Saharan African setting.Cardiovasc J Afr 2019;30 :317–20.
doi:10.5830/cvja-2019-024
30 Raphael DM, Roos L, Myovela V, et al. Heart diseases and
echocardiography in rural Tanzania: Occurrence, characteristics, and
etiologies of underappreciated cardiac pathologies. PLoS One2018;13 :e0208931. doi:10.1371/journal.pone.0208931
31 Stenumgård PS, Rakotondranaivo MJ, Sletvold O, et al. Stroke
in a resource-constrained hospital in Madagascar. BMC Res Notes2017;10 :307. doi:10.1186/s13104-017-2627-4
32 Maramba A, Ncube S, Mandisodza A, et al. An Assessment of the
Effectiveness of Warfarin Therapy Monitoring Systems on Thrombophilic
Patients in Zimbabwe. TH Open 2018;02 :e325–8.
doi:10.1055/s-0038-1672186
33 Noubiap JJ, Nyaga UF. A review of the epidemiology of atrial
fibrillation in sub-Saharan Africa. J Cardiovasc Electrophysiol2019;30 :3006–16. doi:10.1111/jce.14222
34 Tegene E, Tadesse I, Markos Y, et al. Prevalence and risk
factors for atrial fibrillation and its anticoagulant requirement in
adults aged ≥40 in Jimma Town, Southwest Ethiopia: A community based
cross-sectional study. IJC Hear Vasc 2019;22 :199–204.
doi:10.1016/j.ijcha.2019.02.003
35 Stambler B, Ngunga L. Atrial fibrillation in Sub-Saharan Africa:
epidemiology, unmet needs, and treatment options. Int J Gen Med2015;8 :231–42. doi:10.2147/IJGM.S84537
36 Ntep-Gweth M, Zimmermann M, Meiltz A, et al. Atrial
fibrillation in Africa: Clinical characteristics, prognosis, and
adherence to guidelines in Cameroon. Europace2010;12 :482–7. doi:10.1093/europace/euq006
37 Zühlke L, Karthikeyan G, Engel ME, et al. Clinical Outcomes in
3343 Children and Adults With Rheumatic Heart Disease From 14 Low- and
Middle-Income Countries. Circulation 2016;134 :1456–66.
doi:10.1161/CIRCULATIONAHA.116.024769
38 Getachew Erkabu S, Agedie Y, Mihretu DD, et al. Ischemic and
Hemorrhagic Stroke in Bahir Dar, Ethiopia: A Retrospective
Hospital-Based Study. J Stroke Cerebrovasc Dis2018;27 :1533–8. doi:10.1016/j.jstrokecerebrovasdis.2017.12.050
39 Shavadia J, Yonga G, Mwanzi S, et al. Clinical characteristics
and outcomes of atrial fibrillation and flutter at the Aga Khan
University Hospital, Nairobi. Cardiovasc J Afr2013;24 :6–9. doi:10.5830/CVJA-2012-064
40 Pastakia SD, Fohl AL, Schellhase EM, et al. Needs assessment
analysis for vitamin K antagonist anticoagulation in the
resource-constrained setting of Eldoret, Kenya. J Am Pharm Assoc2010;50 :723–5. doi:10.1331/JAPhA.2010.09226
41 Sidibé S, Sako M, Sacko A, et al. Problématique de
l’anticoagulation dans la fibrillation atriale non valvulaire du sujet
âgé. Research 2018;fr5 :2618. doi:10.13070/rs.fr.5.2618
42 Moloi AH, Mall S, Engel ME, et al. The Health Systems Barriers
and Facilitators for RHD Prevalence: An Epidemiological Meta-Analysis
From Uganda and Tanzania. Glob Heart 2017;12 :5–15.
doi:10.1016/j.gheart.2016.12.002
43 Zühlke LJ, Engel ME, Watkins D, et al. Incidence, prevalence
and outcome of rheumatic heart disease in South Africa: A systematic
review of contemporary studies. Int J Cardiol2015;199 :375–83. doi:10.1016/j.ijcard.2015.06.145
44 Keates AK, Mocumbi AO, Ntsekhe M, et al. Cardiovascular
disease in Africa: epidemiological profile and challenges. Nat Rev
Cardiol 2017;14 :273–93. doi:10.1038/nrcardio.2017.19
45 Kane A, Mirabel M, Touré K, et al. Echocardiographic screening
for rheumatic heart disease: Age matters. Int J Cardiol2013;168 :888–91. doi:10.1016/j.ijcard.2012.10.090
46 Longo-Mbenza B, Bayekula M, Ngiyulu R, et al. Survey of
rheumatic heart disease in school children of Kinshasa town. Int J
Cardiol 1998;63 :287–94. doi:10.1016/S0167-5273(97)00311-2
47 Engel ME, Haileamlak A, Zühlke L, et al. Prevalence of
rheumatic heart disease in 4720 asymptomatic scholars from South Africa
and Ethiopia. Heart 2015;101 :1389–94.
doi:10.1136/heartjnl-2015-307444
48 Chang AY, Nabbaale J, Okello E, et al. Outcomes and Care
Quality Metrics for Women of Reproductive Age Living With Rheumatic
Heart Disease in Uganda. J Am Heart Assoc2020;9 :e015562. doi:10.1161/JAHA.119.015562
49 Danwang C, Temgoua MN, Agbor VN, et al. Epidemiology of venous
thromboembolism in Africa: a systematic review. J Thromb Haemost2017;15 :1770–81. doi:10.1111/jth.13769
50 Durand M, Sinyavskaya L, Jin YL, et al. Incidence of venous
thromboembolism in patients living with HIV: A cohort study. AIDS
Patient Care STDS 2019;33 :455–8. doi:10.1089/apc.2019.0154
51 Vululi ST, Bugeza S, Zeridah M, et al. Prevalence of lower
limb deep venous thrombosis among adult HIV positive patients attending
an outpatient clinic at Mulago Hospital. AIDS Res Ther2018;15 :3. doi:10.1186/s12981-018-0191-1
52 Mampuya FK, Steinberg WJ, Raubenheimer JE. Risk factors and HIV
infection among patients diagnosed with deep vein thrombosis at a
regional/tertiary hospital in Kimberley, South Africa. South
African Fam Pract 2018;60 :107–13.
doi:10.1080/20786190.2018.1432135
53 Louw S, Jacobson BF, Büller H. Human Immunodeficiency Virus Infection
and Acute Deep Vein Thromboses. Clin Appl Thromb2008;14 :352–5. doi:10.1177/1076029607304411
54 Goldstein LN, Wu MT. A one year audit of patients with venous
thromboembolism presenting to a tertiary hospital in Johannesburg, South
Africa. African J Emerg Med 2018;8 :12–5.
doi:10.1016/j.afjem.2017.08.006
55 Awolesi D, Naidoo M, Cassimijee MH. The profile and frequency of
known risk factors or comorbidities for deep vein thrombosis in an urban
district hospital in KwaZulu-Natal. South Afr J HIV Med2016;17 :a425. doi:10.4102/sajhivmed.v17i1.425
56 Olubanwo OO. The profile of HIV / AIDS patients admitted with
deep venous thrombosis (DVT) at Nelson Mandela Hospital in Mthatha,
South Africa . 2010.http://hdl.handle.net/10019.1/100702
57 Alshehri MF. Risk factors for Deep Vein Thrombosis in a South
African public hospital . 2013.http://hdl.handle.net/11427/2879
58 Kamdem F, Hugo BMN, Hamadou B, et al. Epidemiology , Clinical
Presentations and In-Hospital Mortality of Venous Thromboembolism at the
Douala General Hospital : A Cross-Sectional Study in Cameroon ,
Sub-Saharan Africa. World J Cardiovasc Dis2018;8 :123–32. doi:10.4236/wjcd.2018.82012
59 Nkoke C, Teuwafeu D, Mapina A, et al. A case series of venous
thromboembolic disease in a semi-urban setting in Cameroon. BMC
Res Notes 2019;12 :40. doi:10.1186/s13104-019-4092-8
60 Abah JP, Menanga A, Ngahane BHM, et al. Pattern of venous
thromboembolic diseases in a resources-limited setting in Cameroon.Pan Afr Med J 2016;23 :236.
doi:10.11604/pamj.2016.23.236.7034
61 Ogeng’o JA, Obimbo MM, Olabu BO, et al. Pulmonary
thromboembolism in an East African tertiary referral hospital. J
Thromb Thrombolysis 2011;32 :386–91.
doi:10.1007/s11239-011-0607-4
62 Johnson LF, May MT, Dorrington RE, et al. Estimating the
impact of antiretroviral treatment on adult mortality trends in South
Africa: A mathematical modelling study. PLOS Med2017;14 :e1002468. doi:10.1371/journal.pmed.1002468
63 UNAIDS. AIDSinfo. 2018.aidsinfo.unaids.org (accessed 11 May 2020).
64 Persaud N, Jiang M, Shaikh R, et al. Global Essential
Medicines Database. 2019. doi:10.6084/m9.figshare.7814246.v1
65 Medicines Patent Pool. Patented medicines that have clinical benefits
but did not meet the EML Expert Review committee’s comparative
cost-effectiveness criterion: Case study on novel oral anticoagulants.
In: Exploring the Expansion of the Medicines Patent Pool’s Mandate
to Patented Essential Medicines: A Feasibility Study of the Public
Health Needs and Potential Impact . Geneva: : Medicines Patent Pool
2015. 64–79.
66 Kibirige D, Atuhe D, Kampiire L, et al. Access to medicines
and diagnostic tests integral in the management of diabetes mellitus and
cardiovascular diseases in Uganda: Insights from the ACCODAD study.Int J Equity Health 2017;16 :154.
doi:10.1186/s12939-017-0651-6
67 Agyepong IA, Sewankambo N, Binagwaho A, et al. The path to
longer and healthier lives for all Africans by 2030: the Lancet
Commission on the future of health in sub-Saharan Africa. Lancet2017;390 :2803–59. doi:10.1016/S0140-6736(17)31509-X
68 Dzudie A, Njume E, Abanda M, et al. Availability, cost and
affordability of essential cardiovascular disease medicines in the south
west region of Cameroon: Preliminary findings from the Cameroon science
for disease study. PLoS One 2020;15 :e0229307.
doi:10.1371/journal.pone.0229307
69 Khuluza F, Haefele-Abah C. The availability, prices and affordability
of essential medicines in Malawi: A cross-sectional study. PLoS
One 2019;14 :e0212125. doi:10.1371/journal.pone.0212125
70 Kanyi J, Karwa R, Pastakia SD, et al. Venous Thromboembolism
Requiring Extended Anticoagulation Among HIV-Infected Patients in a
Rural, Resource-Constrained Setting in Western Kenya. Ann
Pharmacother 2017;51 :380–7. doi:10.1177/1060028016686106
71 Talle M, Bonny A, Scholtz W, et al. Status of cardiac
arrhythmia services in Africa in 2018: a PASCAR Sudden Cardiac Death
Task Force report. Cardiovasc J Afr 2018;29 :115–21.
doi:10.5830/CVJA-2018-027
72 OpenUp. What should your medicines cost? mpr.code4sa.org (accessed 11
May 2020).
73 Bista D, Chalmers L, Bereznicki L, et al. Potential use of
NOACs in developing countries: Pros and cons. Eur J Clin
Pharmacol 2014;70 :817–28. doi:10.1007/s00228-014-1693-y
74 Olsson S, Pal SN, Dodoo A. Pharmacovigilance in resource-limited
countries. Expert Rev Clin Pharmacol 2015;8 :449–60.
doi:10.1586/17512433.2015.1053391
75 Antignac M, Diop BI, Do B, et al. Quality Assessment of 7
Cardiovascular Drugs in 10 Sub-Saharan Countries. JAMA Cardiol2017;2 :223. doi:10.1001/jamacardio.2016.3851
76 Rudd KM, Dier JG. Comparison of two different models of
anticoagulation management services with usual medical care.Pharmacotherapy 2010;30 :330–8.
doi:10.1592/phco.30.4.330
77 Barnes GD, Kline-Rogers E, Graves C, et al. Structure and
function of anticoagulation clinics in the United States: an AC forum
membership survey. J Thromb Thrombolysis 2018;46 :7–11.
doi:10.1007/s11239-018-1652-z
78 Garrison SR, Allan GM. Do specialty anticoagulation clinics really
outperform primary care at INR management? J Thromb Thrombolysis2014;38 :420–1. doi:10.1007/s11239-014-1113-2
79 McGuinn TL, Scherr S. Anticoagulation clinic versus a traditional
warfarin management model. Nurse Pract 2014;39 :40–6.
doi:10.1097/01.NPR.0000451803.29453.0c
80 Wilson SJ-A, Wells PS, Kovacs MJ, et al. Comparing the quality
of oral anticoagulant management by anticoagulation clinics and by
family physicians: a randomized controlled trial. CMAJ2003;169 :293–8.https://www.cmaj.ca/content/169/4/293
81 Matchar DB. Do Anticoagulation Management Services Improve Care?
Implications of the Managing Anticoagulation Services Trial. Card
Electrophysiol Rev 2003;7 :379–81.
doi:10.1023/B:CEPR.0000023144.60821.d1
82 Assefa T, Gedif T, Alemayehu B. Evaluation of Patients’ Knowledge on
Warfarin Therapy Among Outpatients Receiving Warfarin at Tikur Anbessa
Specialized Hospital, Addis Ababa, Ethiopa. Ethiop Pharm J2014;30 :133–8. doi:10.4314/epj.v30i2.6
83 Nyamu D, Guantai A. Patterns of Ambulatory Anticoagulation Practices
in a County Hospital in Nairobi. Pharm J Kenya2018;23 :75–82.https://psk.or.ke/journals/article-25
84 Dejene F, Berihun D, Assefa T. Healthcare Professionals’ Knowledge
and Counseling Practice on Warfarin Therapy at Tertiary Care Teaching
Hospital, Addis Ababa, Ethiopia. Cardiovasc Pharmacol Open Access2017;6 :206. doi:10.4172/2329-6607.1000206
85 Tadesse TA, Alebachew M, Woldu A. Prevalence of Warfarin Drug
Interaction and Warfarin Education Practice in Outpatient Setups of
University Teaching Hospital: A Retrospective Chart Review and an
Observational Study. J Basic Clin Pharm2018;9 :262–6.https://www.jbclinpharm.org/articles/prevalence-of-warfarin-drug-interaction-and-warfarin-educationpractice-in-outpatient-setups-of-university-teaching-hospi.pdf
86 Jacobs A, Bassa F, Decloedt EH. A preliminary review of warfarin
toxicity in a tertiary hospital in Cape Town, South Africa.Cardiovasc J Afr 2017;28 :346–9.
doi:10.5830/CVJA-2017-029
87 Abok II, Andeyaba B, Slusher T, et al. Point-of-care
monitoring of international normalized ratio among patients with
mechanical valves in Jos, North-Central, Nigeria. Niger J Cardiol2019;16 :98–102. doi:10.4103/njc.njc_39_17
88 Goma F, Kalinchenko S. Atrial Fibrillation in Lusaka –
Pathoaetiology, Pathophysiology and Clinical Management Challenges in
Primary Care Settings. Med J Zambia2015;42 :31–41.https://www.mjz.co.zm/index.php/mjz/article/view/275
89 Benade EL, Jacobson BF, Louw S, et al. Validation of the
CoaguChek XS international normalised ratio point-of-care analyser in
patients at Charlotte Maxeke Johannesburg Academic Hospital, South
Africa. South African Med J 2016;106 :280–3.
doi:10.7196/SAMJ.2016.v106i3.9422
90 Agyepong-Yeboah AA. Comparison of the International Normalised
Ratios obtained by the CoaguChek® XS coagulometer and by the Haematology
Laboratory for patients on warfarin therapy at Dr George Mukhari
Hospital: Gauteng Province .
2014.https://repository.smu.ac.za/handle/20.500.12308/104
91 Mbokota N, Schapkaitz E, Louw S. Verification of the qLabs
international normalized ratio point-of-care device for monitoring of
patients attending an anticoagulation clinic. Int J Lab Hematol2018;40 :508–14. doi:10.1111/ijlh.12849
92 Kamuren Z, Kigen G, Keter A, et al. Characteristics of
patients with thromboembolic disorders on warfarin therapy in resource
limited settings. BMC Health Serv Res 2018;18 :723.
doi:10.1186/s12913-018-3537-4
93 Nyandigisi EM. Comparative Effectiveness and Cost Analysis of
an Anticoagulation Clinic Versus Laboratory Based Practice in Kenyan
Tertiary Referral Hospitals .
2018.http://erepository.uonbi.ac.ke/handle/11295/104521
94 Canadian Agency for Drugs and Technologies in Health. Point-of-Care
Testing of International Normalized Ratio for Patients on Oral
Anticoagulant Therapy: Systematic Review and Economic Analysis. Ottawa:
: The Agency 2014. http://www.cadth.ca/media/pdf/OP0515_POC
INR_Science_Report.pdf
95 Anakwue R, Nwagha T, Ukpabi O, et al. A Survey of Clinicians
Practice Patterns in Anticoagulation Therapy & Prophylaxis in Nigeria.Haematol Int J 2018;2 :1–8. doi:10.23880/HIJ-16000125
96 Ministry of Health Ghana. Standard Treatment Guidelines . Sixth
edit. Accra: : Ghana National Drugs Programme 2010.
97 Ministry of Health and Social Services Namibia. Namibia
Standard Treatment Guidelines . First edit. Windhoek: : Ministry of
Health and Social Services 2011.
98 Food Medicine and Health Care Administration and Control Authority
Ethiopia. Standard Treatment Guidelines for General Hospitals .
Third edit. Addis Ababa: : Food Medicine and Health Care Administration
and Control Authority 2014.
99 Ministry of Health Uganda. Uganda Clinical Guidelines 2016.
National Guidelines for Mangaement of Common Conditions . Kampala: :
Ministry of Health 2016.
100 Division of Non-Communicable Diseases Ministry of Health Kenya.Kenya National Guidelines for Cardiovascular Diseases Management .
Nairobi: : Ministry of Health 2018.
101 National Department of Health South Africa. Standard Treatment
Guidelines And Essential Medicines List for South Africa: Hospital
Level, Adults . 5th edit. Pretoria: : National Department of Health
2019.
102 Van Spall HGC, Wallentin L, Yusuf S, et al. Variation in
warfarin dose adjustment practice is responsible for differences in the
quality of anticoagulation control between centers and countries: An
analysis of patients receiving warfarin in the RE-LY trial.Circulation 2012;126 :2309–16.
doi:10.1161/CIRCULATIONAHA.112.101808
103 Hill SW, Varker AS, Karlage K, et al. Analysis of drug
content and weight uniformity for half-tablets of 6 commonly split
medications. J Manag Care Pharm 2009;15 :253–61.
doi:10.18553/jmcp.2009.15.3.253
104 Asiimwe IG, Zhang EJ, Osanlou R, et al. Genetic Factors
Influencing Warfarin Dose in Black‐African Patients: A Systematic Review
and Meta‐Analysis. Clin Pharmacol Ther2020;107 :1420–33. doi:10.1002/cpt.1755
105 Teklay G, Shiferaw N, Legesse B, et al. Drug-drug
interactions and risk of bleeding among inpatients on warfarin therapy:
A prospective observational study. Thromb J 2014;12 :20.
doi:10.1186/1477-9560-12-20
106 Maina MW, Pastakia SD, Manji I, et al. Describing the profile
of patients on concurrent rifampin and warfarin therapy in Western
Kenya: A case series. Drugs R D 2013;13 :191–7.
doi:10.1007/s40268-013-0023-7
107 Sekaggya C, Nalwanga D, Von Braun A, et al. Challenges in
achieving a target international normalized ratio for deep vein
thrombosis among HIV-infected patients with tuberculosis: A case series.BMC Hematol 2016;16 :16. doi:10.1186/s12878-016-0056-6
108 Tarus NK, Pau AK, Sereti I, et al. Challenges in Management
of Warfarin Anti-Coagulation in Advanced HIV/AIDS Patients with Venous
Thrombotic Events - A Case Series from a Research Clinic in Rural
Kericho, Kenya. East Afr Med J2013;90 :207–13.https://www.ajol.info/index.php/eamj/article/view/108234
109 Ahmed SM, Nordeng H, Sundby J, et al. The use of medicinal
plants by pregnant women in Africa: A systematic review. J
Ethnopharmacol 2018;224 :297–313.
doi:10.1016/j.jep.2018.05.032
110 Liwa AC, Smart LR, Frumkin A, et al. Traditional Herbal
Medicine Use Among Hypertensive Patients in Sub-Saharan Africa: A
Systematic Review. Curr Hypertens Rep 2014;16 :437.
doi:10.1007/s11906-014-0437-9
111 Cordier W, Steenkamp V. Herbal remedies affecting coagulation: A
review. Pharm Biol 2012;50 :443–52.
doi:10.3109/13880209.2011.611145
112 Awortwe C, Makiwane M, Reuter H, et al. Critical evaluation
of causality assessment of herb–drug interactions in patients. Br
J Clin Pharmacol 2018;84 :679–93. doi:10.1111/bcp.13490
113 Mariita K, Nyamu D, Maina C, et al. Patient Associated
Factors that Affect Adherence to Warfarin Therapy in a Tertiary Referral
Hospital in Kenya. East Cent African J Pharm Sci2015;18 :43–50.https://www.ajol.info/index.php/ecajps/article/view/177867
114 Chang AY, Nabbaale J, Nalubwama H, et al. Motivations of
women in Uganda living with rheumatic heart disease: A mixed methods
study of experiences in stigma, childbearing, anticoagulation, and
contraception. PLoS One 2018;13 :e0194030.
doi:10.1371/journal.pone.0194030
115 Morisky DE, Ang A, Krousel-Wood M, et al. Predictive validity
of a medication adherence measure in an outpatient setting. J Clin
Hypertens 2008;10 :348–54.
doi:10.1111/j.1751-7176.2008.07572.x
116 Iqbal S. Effect of a Designed Warfarin Based Education Program
on Patients’ Knowledge and Anticoagulation Control Among Adult
Outpatients Attending Clinics at Kenyatta National Hospital .
2017.http://erepository.uonbi.ac.ke/handle/11295/103355
117 Eltayeb TYM, Mohamed MS, Elbur AI, et al. Satisfaction with
and adherence to warfarin treatment: A cross-sectional study among
Sudanese patients. J Saudi Hear Assoc 2017;29 :169–75.
doi:10.1016/j.jsha.2016.10.007
118 Morisky DE, Green LW, Levine DM. Concurrent and Predictive Validity
of a Self-reported Measure of Medication Adherence. Med Care1986;24 :67–74. doi:10.1097/00005650-198601000-00007
119 Dwamena JA. Knowledge Level and Anticoagulation Control Among
Patient on Warfarin Therapy at the National Cardiothoracic Center, Korle
Bu Teaching Hospital .
2012.http://ugspace.ug.edu.gh/handle/123456789/23702%09
120 Gregersen NE. The implications to women of childbearing age
taking Warfarin Anticoagulation . 2006.http://hdl.handle.net/10539/1838
121 Taylor FC, Ramsay ME, Tan G, et al. Evaluation of patients’
knowledge about anticoagulant treatment. Qual Heal Care1994;3 :79–85. doi:10.1136/qshc.3.2.79
122 Briggs AL, Jackson TR, Bruce S, et al. The development and
performance validation of a tool to assess patient anticoagulation
knowledge. Res Soc Adm Pharm 2005;1 :40–59.
doi:10.1016/j.sapharm.2004.12.002
123 Zeolla MM, Brodeur MR, Dominelli A, et al. Development and
validation of an instrument to determine patient knowledge: The oral
anticoagulation knowledge test. Ann Pharmacother2006;40 :633–8. doi:10.1345/aph.1G562
124 Hutheram K. Investigating Patients’ Knowledge and Use of the
Patient Information Leaflet Regarding Their Warfarin Therapy .
2016.http://hdl.handle.net/10413/17693
125 Samadoulougou A, Temoua Naibe D, Mandi G, et al. Evaluation
of the level of knowledge of patients on treatment with vitamin K
antagonists in Ouagadougou cardiology department. Pan Afr Med J2014;19 :286. doi:10.11604/pamj.2014.19.286.5411
126 Janoly-Duménil A, Bourne C, Loiseau K, et al. Traitement
anticoagulant oral - Évaluation des connaissances des patients
hospitalisés en services de médecine physique et réadaptation. Ann
Phys Rehabil Med 2011;54 :172–80.
doi:10.1016/j.rehab.2011.02.007
127 Ng SS, Lai NM, Nathisuwan S, et al. Comparative efficacy and
safety of warfarin care bundles and novel oral anticoagulants in
patients with atrial fibrillation: a systematic review and network
meta-analysis. Sci Rep 2020;10 :662.
doi:10.1038/s41598-019-57370-2
128 Rabkin M, Melaku Z, Bruce K, et al. Strengthening Health
Systems for Chronic Care: Leveraging HIV Programs to Support Diabetes
Services in Ethiopia and Swaziland. J Trop Med2012;2012 :137460. doi:10.1155/2012/137460
129 Yiu A, Bajorek B. Patient-focused interventions to support
vulnerable people using oral anticoagulants: a narrative review.Ther Adv Drug Saf 2019;10 :1–27.
doi:10.1177/2042098619847423
130 Kanters S, Park JJH, Chan K, et al. Interventions to improve
adherence to antiretroviral therapy: a systematic review and network
meta-analysis. Lancet HIV 2017;4 :e31–40.
doi:10.1016/S2352-3018(16)30206-5
131 Rusingiza EK, El-Khatib Z, Hedt-Gauthier B, et al. Outcomes
for patients with rheumatic heart disease after cardiac surgery followed
at rural district hospitals in Rwanda. Heart2018;104 :1707–13. doi:10.1136/heartjnl-2017-312644
132 Wiggins BS, Dixon DL, Neyens RR, et al. Select Drug-Drug
Interactions With Direct Oral Anticoagulants: JACC Review Topic of the
Week. J Am Coll Cardiol 2020;75 :1341–50.
doi:10.1016/j.jacc.2019.12.068